Treatment of colorectal liver metastases using talaporfin sodium and intratumoral placement of LEDs

3663 Background: Recurrent or refractory liver metastases from colorectal cancer (CRC) leave few options after failure of multiple standard therapies. Patients require creative applications of combination therapies to reduce tumor burden. Aggressive but minimally morbid treatments may prolong and improve period of disease control. Method: 17 lesions in 10 patients were treated in a Phase II study using a percutaneous ablative interstitial light activation system (Litx) that combines a photosensitizing drug with light of a specific wavelength delivered to the center of the tumor that results in tumor destruction. Eligibility for enrollment included 1 or more unresectable ≤ 7cm hepatic lesions metastatic from CRC. Up to 4 Litx devices were placed in up to 4 lesions per patient to photoactivate talaporfin sodium administered intravenously at a dose of 1 mg/kg. Percutaneous insertion of each device was guided by computed tomography (CT) or ultrasound. After a 15 to 60 minute interval, Litx devices were activa...